Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.

Trial Profile

Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Alveolar soft part sarcoma; Anaplastic large cell lymphoma; Clear cell sarcoma; Muscle tissue neoplasms; Renal cancer; Rhabdomyosarcoma
  • Focus Therapeutic Use
  • Acronyms CREATE
  • Most Recent Events

    • 18 Sep 2017 Results of cohort of patients with clear cell sarcoma (n=36) published in the Annals of Oncology
    • 09 Aug 2017 The trial was prematurely ended in Denmark.
    • 04 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top